NASDAQ:ALKS - Alkermes Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $22.20
Forecasted Upside: -9.09 %
Number of Analysts: 6
Breakdown:
1 Sell Ratings
4 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$24.42 As of 06/18/2021 01:00 AM ET

▼ -0.27 (-1.09%)

1 month | 3 months | 12 months

Get New Alkermes Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ALKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALKS

^$22.20

▼ -9.09% Downside Potential

This price target is based on 6 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $22.20, with a high forecast of $29.00 and a low forecast of $15.00. The average price target represents a -9.09% upside from the last price of $24.42.

Hold

The current consensus among 6 investment analysts is to hold stock in Alkermes. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
7 hold ratings
2 sell ratings

Ratings as of

12/28/2019

0 strong buy ratings
2 buy ratings
8 hold ratings
2 sell ratings

Ratings as of

3/27/2020

0 strong buy ratings
2 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

6/25/2020

0 strong buy ratings
2 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

9/23/2020

0 strong buy ratings
2 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

12/22/2020

0 strong buy ratings
1 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
1 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/21/2021

0 strong buy ratings
1 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/2/2021	HC Wainwright	Boost Price Target	Neutral	$24.00 ➝ $25.00	Low
6/1/2021	Mizuho	Reiterated Rating	Buy	$29.00	High
4/29/2021	HC Wainwright	Boost Price Target	Neutral	$23.00 ➝ $24.00	Low
4/26/2021	Mizuho	Boost Price Target	Buy	$28.00 ➝ $29.00	High
1/7/2021	Mizuho	Boost Price Target		$24.00 ➝ $28.00	N/A
12/11/2020	SVB Leerink	Boost Price Target	Market Perform	$18.00 ➝ $23.00	Medium
11/10/2020	HC Wainwright	Reiterated Rating	Hold		Low
10/15/2020	Mizuho	Upgrade	Neutral ➝ Buy	$19.00 ➝ $24.00	Low
10/7/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
9/30/2020	Bank of America	Lower Price Target	Neutral	$21.00 ➝ $19.00	Medium
9/21/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
7/30/2020	HC Wainwright	Reiterated Rating	Hold	$23.00	Medium
7/30/2020	Mizuho	Boost Price Target	Neutral	$16.00 ➝ $19.00	High
7/30/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$19.00 ➝ $15.00	High
4/30/2020	HC Wainwright	Reiterated Rating	Neutral	$25.00 ➝ $23.00	High
4/29/2020	Piper Sandler	Lower Price Target	Neutral	$22.00 ➝ $21.00	High
4/29/2020	Stifel Nicolaus	Lower Price Target	Average ➝ Hold	$20.00 ➝ $17.00	High
4/29/2020	Mizuho	Reiterated Rating	Hold	$16.00	High
4/2/2020	Morgan Stanley	Lower Price Target	Equal Weight	$20.00 ➝ $16.00	Low
3/23/2020	Bank of America	Lower Price Target	Neutral	$20.00 ➝ $17.00	Medium
2/14/2020	HC Wainwright	Lower Price Target	Neutral	$26.00 ➝ $25.00	High
2/14/2020	Bank of America	Downgrade	Buy ➝ Neutral	$31.00 ➝ $20.00	High
2/14/2020	Cowen	Reiterated Rating	Buy	$28.00	High
2/13/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$25.00 ➝ $21.00	Low
2/13/2020	Stifel Nicolaus	Lower Price Target	Hold	$23.00 ➝ $20.00	Low
2/5/2020	Mizuho	Initiated Coverage	Neutral	$19.00	Medium
1/31/2020	Wolfe Research	Upgrade	Underperform ➝ Peer Perform	$21.00	Low
1/24/2020	SVB Leerink	Reiterated Rating	Market Perform		Low
1/24/2020	Cowen	Reiterated Rating	Buy		High
11/1/2019	HC Wainwright	Lower Price Target	Neutral	$28.00 ➝ $26.00	Low
10/23/2019	Stifel Nicolaus	Lower Price Target	Hold	$25.00 ➝ $23.00	High
10/18/2019	HC Wainwright	Reiterated Rating	Hold	$28.00	Low
9/13/2019	Cowen	Set Price Target	Buy	$34.00	High
9/5/2019	Morgan Stanley	Upgrade	Underweight ➝ Equal	$30.00 ➝ $20.00	Medium
7/26/2019	Citigroup	Set Price Target	Hold	$25.00	N/A
7/25/2019	Piper Jaffray Companies	Lower Price Target	Neutral	$30.00 ➝ $22.00	Medium
7/15/2019	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$27.00	High
5/31/2019	HC Wainwright	Initiated Coverage	Neutral ➝ Neutral	$28.00 ➝ $28.00	High
5/1/2019	Citigroup	Downgrade	Buy ➝ Neutral	$62.00 ➝ $33.00	High
4/26/2019	Credit Suisse Group	Set Price Target	Sell	$28.00	Medium
4/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
2/15/2019	Credit Suisse Group	Upgrade	Hold	$30.00	High
2/15/2019	Stifel Nicolaus	Lower Price Target	Hold	$40.00 ➝ $34.00	N/A
1/23/2019	Cantor Fitzgerald	Set Price Target	Hold	$33.00	Low
1/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
12/18/2018	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$49.00 ➝ $26.00	High
12/14/2018	Wolfe Research	Initiated Coverage	Underperform ➝ Underperform		Medium
12/13/2018	Credit Suisse Group	Downgrade	Outperform ➝ Underperform	$47.00 ➝ $31.00	High
11/12/2018	SVB Leerink	Initiated Coverage	Market Perform	$36.00	Medium
11/5/2018	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$46.00 ➝ $41.00	High
11/5/2018	Piper Jaffray Companies	Initiated Coverage	Neutral ➝ Neutral	$40.00	Low
11/2/2018	Stifel Nicolaus	Lower Price Target	Hold	$44.00 ➝ $40.00	High
10/30/2018	Cowen	Reiterated Rating	Buy	$58.00	Medium
10/23/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$46.00	Low
8/6/2018	Stifel Nicolaus	Initiated Coverage	Hold	$45.00	Low
7/27/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Buy	$57.00 ➝ $51.00	High
7/27/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$56.00 ➝ $54.00	High
7/8/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
7/2/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
6/28/2018	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight		Low
6/21/2018	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$67.00 ➝ $42.00	High
6/6/2018	B. Riley	Initiated Coverage	Buy	$60.00	High
5/31/2018	Citigroup	Upgrade	Neutral ➝ Buy		Medium
5/16/2018	Citigroup	Upgrade	Neutral ➝ Buy	$62.00	High
5/11/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$56.00	Medium
4/27/2018	Credit Suisse Group	Set Price Target	Buy	$57.00	Low
4/16/2018	Credit Suisse Group	Set Price Target	Buy	$63.00	Medium
4/3/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$63.00	High
4/2/2018	Cowen	Lower Price Target	Outperform	$55.00	High
4/2/2018	Credit Suisse Group	Reiterated Rating	Buy	$53.00	High
4/2/2018	Cantor Fitzgerald	Lower Price Target	Neutral	$45.00	High
2/23/2018	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$60.00 ➝ $67.00	Medium
2/22/2018	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$63.19 ➝ $66.00	High
2/20/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$50.00	Medium
2/16/2018	Credit Suisse Group	Boost Price Target	Outperform	$66.00 ➝ $70.00	High
2/15/2018	Citigroup	Set Price Target	Hold	$62.00	High
2/14/2018	Credit Suisse Group	Set Price Target	Buy	$66.00	High
11/28/2017	Credit Suisse Group	Set Price Target	Buy	$66.00	Medium
10/27/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$78.00	N/A
10/27/2017	UBS Group	Set Price Target	Hold	$57.00 ➝ $54.00	N/A
10/27/2017	Credit Suisse Group	Lower Price Target	Outperform	$70.00 ➝ $66.00	N/A
10/26/2017	Barclays	Set Price Target	Hold	$50.00	N/A
10/26/2017	Citigroup	Set Price Target	Hold	$62.00	N/A
10/21/2017	Mizuho	Set Price Target	Buy	$81.00	N/A
10/16/2017	Barclays	Downgrade	Overweight ➝ Equal Weight	$66.00 ➝ $50.00	N/A
8/25/2017	Jefferies Financial Group	Set Price Target	Buy	$69.00	Low
7/1/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$78.00	Low
6/13/2017	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$68.00 ➝ $61.00	Medium
6/7/2017	Credit Suisse Group	Reiterated Rating	Buy	$70.00	Low
5/19/2017	Credit Suisse Group	Set Price Target	Buy	$70.00	Low
4/28/2017	Cowen	Reiterated Rating	Buy		Low
4/27/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$78.00	Medium
4/24/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$62.00	Low
4/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$70.00	Medium
3/21/2017	Cowen	Reiterated Rating	Positive	$65.00	Low
3/16/2017	Cantor Fitzgerald	Reiterated Rating	Neutral	$51.00	Medium
2/16/2017	Cantor Fitzgerald	Reiterated Rating	Neutral	$51.00	N/A
12/21/2016	Cantor Fitzgerald	Reiterated Rating	Neutral	$52.00	N/A
12/15/2016	Cantor Fitzgerald	Initiated Coverage	Neutral	$52.00	N/A
11/17/2016	Jefferies Financial Group	Reiterated Rating	Buy	$70.00	N/A
11/2/2016	Cowen	Reiterated Rating	Buy		N/A
10/24/2016	UBS Group	Set Price Target	Hold	$57.00	N/A
10/21/2016	Morgan Stanley	Upgrade	Underweight ➝ Hold	$62.00	N/A
10/21/2016	Jefferies Financial Group	Boost Price Target	Buy	$62.00 ➝ $70.00	N/A
10/21/2016	SVB Leerink	Boost Price Target	Outperform	$57.00 ➝ $70.00	N/A
10/21/2016	Credit Suisse Group	Boost Price Target	Outperform	$52.00 ➝ $70.00	N/A
10/21/2016	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$51.00 ➝ $78.00	N/A
10/20/2016	Cowen	Set Price Target	Buy	$60.00	N/A
10/4/2016	SVB Leerink	Initiated Coverage	Outperform	$57.00	N/A
9/27/2016	Citigroup	Boost Price Target	Neutral	$44.00 ➝ $53.00	N/A
9/23/2016	Cowen	Reiterated Rating	Buy		N/A
9/2/2016	Morgan Stanley	Reiterated Rating	Sell	$41.00	N/A
7/29/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$51.00	N/A
7/29/2016	Jefferies Financial Group	Boost Price Target	Buy	$54.00 ➝ $62.00	N/A
7/29/2016	Barclays	Boost Price Target	Overweight	$65.00 ➝ $66.00	N/A
7/17/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
7/13/2016	Barclays	Boost Price Target	Overweight	$50.00 ➝ $65.00	N/A
7/12/2016	Barclays	Reiterated Rating	Buy	$50.00 ➝ $65.00	N/A
6/29/2016	UBS Group	Reiterated Rating	Hold	$34.00 ➝ $41.00	N/A
6/28/2016	SVB Leerink	Reiterated Rating	Outperform	$58.00 ➝ $54.00	N/A

(Data available from 6/20/2016 forward)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $24.42

$24.36

$24.62

50 Day Range

MA: $22.27

$18.78

$25.15

52 Week Range

Now: $24.42

$15.35

$25.47

Volume

2,547,234 shs

Average Volume

1,535,330 shs

Market Capitalization

$3.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Alkermes?

The following sell-side analysts have issued stock ratings on Alkermes in the last year: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Mizuho, SVB Leerink LLC, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for ALKS.

What is the current price target for Alkermes?

5 Wall Street analysts have set twelve-month price targets for Alkermes in the last year. Their average twelve-month price target is $22.20, suggesting a possible downside of 9.1%. Mizuho has the highest price target set, predicting ALKS will reach $29.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $15.00 for Alkermes in the next year.
View the latest price targets for ALKS.

What is the current consensus analyst rating for Alkermes?

Alkermes currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALKS, but not buy more shares or sell existing shares.
View the latest ratings for ALKS.

What other companies compete with Alkermes?

Other companies that are similar to Alkermes include Amgen, Gilead Sciences, Biogen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Alkermes' investor relations team?

Alkermes' physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company's listed phone number is 353-1772-8000 and its investor relations email address is [email protected] The official website for Alkermes is www.alkermes.com.